Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HBsAg+~* Anti-HBs negative~* HBV titer \> 1x10\^7 copies / ml~* Treatment naïve~* HIV / HCV / hepatitis delta virus negative~* Fibrosis with compensation (as determined by Fibroscan and liver enzymes)~* Non cirrhotic~* No known active cytomegalovirus infection~* Willingness to utilize adequate contraception while being treated with REP 9AC' and for 6 months following the end of treatment~* Adequate venous access allowing weekly intravenous therapies and blood tests~Exclusion Criteria:~* Evidence of cardiovascular disease~* Autoimmune hepatitis~* Presence of Wilson's disease~* Presence of severe NAFLD~* Evidence of any other co-existent liver disease~* Anti-nuclear antibody positive~* Evidence of liver cirrhosis~* A history of ascites, hepatic encephalopathy or variceal hemorrhage~* Body weight \> 100 kg~* Platelet count \< 75,000, polymorphonuclear cell count \< 1,500 or hematocrit \< 33%~* Alpha feto protein \> 100 ng/ml or the presence of a hepatic mass suggestive of hepatocellular carcinoma .~* Bilirubin \> 2.5 mg/dl~* Creatinine \> 1.5 mg/dl~* Platelet count \< 75,000 / cmm~* Serum albumin \< 35 mg/ml~* Poorly controlled diabetes mellitus~* Another serious medical disorder~* A serious psychiatric disorder~* Uncontrolled hypertension~* A history of alcohol abuse within the last year~* The use of illicit drugs within the past two years~* Inability to provide informed consent~* Positive pregnancy test~* Breastfeeding~* Inability or unwillingness to provide weekly blood samples~* Poor venous access making IV infusion too difficult

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- REP 2139-Ca + immunotherapy (Type: EXPERIMENTAL): REP 2139-Ca is the calcium chelate complex formulation of REP 2139.~Zadaxin is thymosin alpha 1~Pegasys is pegylated interferon alpha 2a~Patients initially receiving REP 2139-Ca with no Grade 3 adverse events at week 20 are eligible to transition to combination therapy with Zadaxin if serum HBV DNA is \> 2000 copies / ml.~After 10 weeks of REP 2139-Ca / Zadaxin combination therapy, patients not experiencing a measurable improvement in serum antiviral response can further transition to combination therapy with REP 2139-Ca and Pegasys.

Based on this trial design, predict the completion outcome and termination type (if applicable).